ENDRA Life Sciences Inc (NDRA) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The company shows weak financial performance, no significant trading trends, and lacks positive catalysts. Additionally, there are no strong trading signals or recent news to support a buy decision.

Technical Analysis

The MACD is positive and expanding (0.0687), which is a mild bullish signal. However, the RSI is neutral at 59.663, and moving averages are converging, indicating no clear trend. The pre-market price is $3.65, down -6.89%, and is approaching the first support level (S1: 3.347). Overall, the technical indicators do not strongly support a buy decision.

Positive Catalysts

NULL identified. No recent news or significant trading trends to act as positive catalysts.

Neutral/Negative Catalysts

The pre-market price is down -6.89%. Financial performance is weak, with a significant YoY drop in net income (-32.20%) and EPS (-99.37%). No recent news or trading signals to counteract these negatives.

Financial Performance

In Q3 2025, revenue remained at $0 with no growth. Net income dropped to -$1,595,959 (-32.20% YoY), and EPS fell to -2.1 (-99.37% YoY). Gross margin remained at 0%. The financials indicate poor performance and a lack of growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

1 Analyst Rating

Wall Street analysts forecast NDRA stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 4.150

Low

Averages

High

Current: 4.150

Low

Averages

High

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$75 → $50

AI Analysis

2025-04-21

Reason